Buys | $0 | 0 | 0 |
Sells | $14,853,821 | 53 | 100 |
Eisele Jeffrey | Chief Development Officer | 0 | $0 | 4 | $57,149 | $-57,149 |
Chopas James George | VP/Chief Accounting Officer | 0 | $0 | 5 | $105,912 | $-105,912 |
Lewis Karen | Chief People Officer | 0 | $0 | 4 | $147,094 | $-147,094 |
Baumal Caroline | Chief Medical Officer | 0 | $0 | 2 | $150,727 | $-150,727 |
Townsend Adam J. | Chief Commercial Officer | 0 | $0 | 4 | $264,626 | $-264,626 |
Nicholson Nur | Chief Technical Officer | 0 | $0 | 4 | $284,281 | $-284,281 |
Sullivan Timothy Eugene | Chief Financial Officer | 0 | $0 | 5 | $458,825 | $-458,825 |
Watson David O. | General Counsel | 0 | $0 | 6 | $641,031 | $-641,031 |
DeLong Mark Jeffrey | Chief Business & Strat Officer | 0 | $0 | 6 | $710,552 | $-710,552 |
Francois Cedric | Chief Executive Officer | 0 | $0 | 4 | $854,932 | $-854,932 |
Dunlop A. Sinclair | director | 0 | $0 | 3 | $3.86M | $-3.86M |
Deschatelets Pascal | Chief Scientific Officer | 0 | $0 | 6 | $7.32M | $-7.32M |
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment …
Over the last 12 months, insiders at Apellis Pharmaceuticals, Inc. have bought $0 and sold $14.85M worth of Apellis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Apellis Pharmaceuticals, Inc. have bought $10.16M and sold $32.96M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500,000 shares for transaction amount of $20M was made by Morningside Venture Investments Ltd (10 percent owner) on 2021‑11‑18.
2025-03-05 | Sale | Watson David O. | General Counsel | 5,569 0.0043% | $25.10 | $139,789 | -3.38% | |
2025-02-11 | Sale | DeLong Mark Jeffrey | Chief Business & Strat Officer | 363 0.0003% | $28.54 | $10,360 | -9.11% | |
2025-01-29 | Sale | Deschatelets Pascal | Chief Scientific Officer | 826 0.0007% | $29.52 | $24,386 | -6.91% | |
2025-01-29 | Sale | Francois Cedric | Chief Executive Officer | 2,824 0.0023% | $29.52 | $83,375 | -6.91% | |
2025-01-29 | Sale | Watson David O. | General Counsel | 695 0.0006% | $29.52 | $20,519 | -6.91% | |
2025-01-29 | Sale | Sullivan Timothy Eugene | Chief Financial Officer | 546 0.0004% | $29.52 | $16,120 | -6.91% | |
2025-01-29 | Sale | DeLong Mark Jeffrey | Chief Business & Strat Officer | 365 0.0003% | $29.52 | $10,776 | -6.91% | |
2025-01-29 | Sale | Townsend Adam J. | Chief Commercial Officer | 695 0.0006% | $29.52 | $20,519 | -6.91% | |
2025-01-29 | Sale | Nicholson Nur | Chief Technical Officer | 825 0.0007% | $29.52 | $24,357 | -6.91% | |
2025-01-29 | Sale | Lewis Karen | Chief People Officer | 364 0.0003% | $29.52 | $10,747 | -6.91% | |
2025-01-29 | Sale | Eisele Jeffrey | Chief Development Officer | 278 0.0002% | $29.52 | $8,208 | -6.91% | |
2025-01-22 | Sale | Deschatelets Pascal | Chief Scientific Officer | 3,948 0.0032% | $30.43 | $120,120 | -7.96% | |
2025-01-22 | Sale | Francois Cedric | Chief Executive Officer | 13,551 0.0109% | $30.43 | $412,296 | -7.96% | |
2025-01-22 | Sale | Watson David O. | General Counsel | 3,323 0.0027% | $30.43 | $101,104 | -7.96% | |
2025-01-22 | Sale | Sullivan Timothy Eugene | Chief Financial Officer | 3,088 0.0025% | $30.43 | $93,954 | -7.96% | |
2025-01-22 | Sale | Townsend Adam J. | Chief Commercial Officer | 3,323 0.0027% | $30.43 | $101,104 | -7.96% | |
2025-01-22 | Sale | DeLong Mark Jeffrey | Chief Business & Strat Officer | 1,396 0.0011% | $30.43 | $42,474 | -7.96% | |
2025-01-22 | Sale | Nicholson Nur | Chief Technical Officer | 3,948 0.0032% | $30.43 | $120,120 | -7.96% | |
2025-01-22 | Sale | Lewis Karen | Chief People Officer | 1,751 0.0014% | $30.43 | $53,275 | -7.96% | |
2025-01-22 | Sale | Eisele Jeffrey | Chief Development Officer | 1,291 0.001% | $30.43 | $39,279 | -7.96% |
Sullivan Timothy Eugene | Chief Financial Officer | 128665 0.1025% | $3.23M | 1 | 14 | +1.94% |
Morningside Venture Investments Ltd | 10 percent owner | 12806342 10.203% | $321.57M | 9 | 0 | +6.91% |
venBio Global Strategic Fund II L.P. | 10 percent owner | 3579305 2.8517% | $89.88M | 1 | 0 | +31.35% |
Hillhouse Capital Management, Ltd. | 10 percent owner | 3527152 2.8101% | $88.57M | 1 | 0 | +31.35% |
Cormorant Asset Management, LLC | 10 percent owner | 3473925 2.7677% | $87.23M | 1 | 0 | +31.35% |
$193,151,375 | 134 | 8.18% | $2.8B | |
$11,588,217 | 69 | 42.07% | $2.65B | |
$140,165,669 | 33 | 85.24% | $3.4B | |
$1,275,975,557 | 32 | 19.44% | $2.87B | |
$5,066,938 | 27 | 26.38% | $2.72B |
Increased Positions | 161 | +51.94% | 32M | +26.74% |
Decreased Positions | 139 | -44.84% | 22M | -18.66% |
New Positions | 60 | New | 9M | New |
Sold Out Positions | 67 | Sold Out | 5M | Sold Out |
Total Postitions | 332 | +7.1% | 129M | +8.08% |
Avoro Capital Advisors Llc | $301,400.00 | 9.7% | 12.22M | +1M | +10% | 2024-12-31 |
Ecor1 Capital, Llc | $293,228.00 | 9.44% | 11.89M | 0 | 0% | 2024-12-31 |
Wellington Management Group Llp | $291,009.00 | 9.37% | 11.8M | -4M | -24.19% | 2024-12-31 |
Vanguard Group Inc | $247,735.00 | 7.97% | 10.05M | +230,450 | +2.35% | 2024-12-31 |
Morgan Stanley | $237,407.00 | 7.64% | 9.63M | +6M | +184.01% | 2024-12-31 |
Blackrock, Inc. | $159,747.00 | 5.14% | 6.48M | +285,621 | +4.61% | 2024-12-31 |
State Street Corp | $111,590.00 | 3.59% | 4.53M | +484,294 | +11.98% | 2024-12-31 |
Deep Track Capital, Lp | $105,420.00 | 3.39% | 4.27M | -125,733 | -2.86% | 2024-12-31 |
Octagon Capital Advisors Lp | $74,152.00 | 2.39% | 3.01M | 0 | 0% | 2024-12-31 |
Siren, L.L.C. | $69,449.00 | 2.24% | 2.82M | +649,034 | +29.95% | 2024-12-31 |